Table 3. The Mean Blood Pressure (MBP) and Heart Rate (HR) after Administration of Reversal Agents.

Time after reverse (min)		Group				P value
		S2	S1	SN	N
MBP (mmHg)	0	77.9 ± 12.7*	74.6 ± 11.6	70.1 ± 10.3†	76.2 ± 11.4*	0.049
	2	77.8 ± 14.2	77.8 ± 13.3	74.5 ± 12.6	77.8 ± 14.6	0.641
	5	79.1 ± 13.7*	83.3 ± 15.6*,†	70.9 ± 10.4	72.4 ± 13.9	0.002
	10	88.2 ± 16.0†	86.7 ± 17.6†	80.1 ± 14.6	75.3 ± 13.1	0.007
HR (bpm)	0	75.4 ± 11.8	73.0 ± 12.2	71.3 ± 12.0	71.1 ± 13.2	0.354
	2	70.5 ± 11.3	71.2 ± 11.1	73.3 ± 11.3	68.6 ± 12.3	0.251
	5	71.3 ± 12.7*,‡	70.1 ± 12.7*,‡	61.5 ± 10.9	58.1 ± 11.7	< 0.001
	10	78.2 ± 12.7*,‡	73.1 ± 12.4‡	69.2 ± 17.8†	56.5 ± 10.3*	< 0.001

Values are expressed as mean ± standard deviation. Group S2: sugammadex 2 mg/kg, Group S1: sugammadex 1 mg/kg, Group SN: sugammadex 1 mg/kg + neostigmine 50 µg/kg + glycopyrrolate 10 µg/kg, Group N: neostigmine 50 µg/kg + glycopyrrolate 10 µg/kg (^*P < 0.05 when compared with group SN, ^†P < 0.05 when compared with group N, ^‡P < 0.001 when compared with group N).